Sinclair Nanopig: The Next Generation, Non-Rodent Model for (Bio)Pharmaceuticals Safety Assessment
Presented by:
Dr. Wendell P. Davis, Vice President, Pathology, Altasciences
Dr. Scott Boley, Senior Scientific Advisor, Altasciences
Derek Brocksmith, General Manager, Sinclair Bio Resources
This webinar was originally presented live by Altasciences on February 22, 2024.
Minipigs have long been utilized in pharmaceutical and medical device development, particularly in toxicology studies for protein and oral small molecule products.
The next generation of the Sinclair Nanopig presents a cost-effective non-rodent species alternative. The Sinclair Nanopig offers several advantages, such as availability of all ages, lower body weight akin to Beagle dogs, comparable toxicological reference data, compatibility with standard routes of administration and sample collection techniques, as well as integrated genotyping and phenotyping data for informed species selection and safety sign comprehension.
In this webinar, we explore:
- The growing use of minipigs in pharmaceutical research;
- The benefits of the next-generation Sinclair Nanopig model as a cost-effective alternative for nonclinical studies, including its availability, lower body weight, and comparable toxicological data to Göttingen minipigs and Beagle dogs.